A short antibiotic course for treating drug-sensitive tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- Your weight must be between 40 and 90 kg (about 88 to 198 pounds).
- You need to have tuberculosis (TB) confirmed in your lungs and be able to produce enough phlegm for testing.
- Your TB must not be resistant to the study drugs, and you must not have taken TB medicines for more than 3 days in the last 6 months.
- You must be generally healthy, with normal liver, kidney, blood, and heart function, and not have HIV, diabetes, or other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study tests a new tuberculosis drug called TBD09 combined with other TB medicines in people with newly diagnosed, drug-sensitive TB. The goal is to see if this combination works well and is safe.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.